Nutriband Inc. announces exercise of warrants at $6.43 for Gross Proceeds of $1,753,274GlobeNewsWire · Oct 13, 2026
Nutriband Files New Patent Application to Strengthen Intellectual Property Protection of Its Transdermal Abuse Deterrent TechnologyGlobeNewsWire · Oct 8, 2026
Nutriband Marks Five Years on Nasdaq – CEO Letter to ShareholdersGlobeNewsWire · Oct 1, 2026
Head to Head Contrast: ARS Pharmaceuticals (NASDAQ:SPRY) and Nutriband (NASDAQ:NTRB)Defense World · Oct 1, 2026
Nutriband CEO Gareth Sheridan Featured in New Nick Shirley Documentary Confronting America's Opioid CrisisGlobeNewsWire · Sep 29, 2026
Nutriband Confirms Warrants Will Expire September 30 Without Extension or RepricingGlobeNewsWire · Sep 22, 2026Nutriband Inc. specializes in developing a diverse range of pharmaceutical products delivered via transdermal patches. The company's most advanced program centers on AVERSA fentanyl, an innovative fentanyl transdermal system engineered to prevent abuse. This extended-release patch provides healthcare professionals and patients with a continuous opioid therapy solution for the ongoing management of chronic pain.
| Date | Est. | Actual | |
|---|---|---|---|
| Sep 4, 2026 | – | -$0.07 | |
| Jun 11, 2026 | -$1.89 | -$0.10 | Beat |
| Apr 29, 2026 | -$1.89 | -$0.04 | Beat |
| Dec 16, 2025 | -$2.13 | -$0.12 | Beat |
| Sep 9, 2025 | -$0.17 | -$2.12 | Miss |
| May 30, 2025 | -$0.13 | -$0.12 | Beat |